HIV, psychosis and aging: Past, present and future

AIDS

Volumn 18, Issue SUPPL. 1, 2004, Pages

  Dolder, Christian R ^a,b   Patterson, Thomas L ^a   Jeste, Dilip V ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

Aging; AIDS; Antipsychotic; HIV; Psychosis

Indexed keywords

ANTIVIRUS AGENT; CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; THIORIDAZINE; ZIPRASIDONE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGE DISTRIBUTION; AGING; ASSOCIATION; CLINICAL FEATURE; CLINICAL TRIAL; COMORBIDITY; CONFERENCE PAPER; DATA BASE; EXTRAPYRAMIDAL SYMPTOM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LOW DRUG DOSE; MEDLINE; MOTOR DYSFUNCTION; PRIORITY JOURNAL; PROGNOSIS; PSYCHOSIS; RISK FACTOR;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AGED; AGING; ANTIPSYCHOTIC AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HIV INFECTIONS; HUMANS; MENTAL DISORDERS; MIDDLE AGED; PROGNOSIS; RISK FACTORS;

EID: 1642282537     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200406002-00005     Document Type: Conference Paper

References (59)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th ed., text revision. Washington, DC: American Psychiatric Association; 2000.
2. Brodt HR, Kamps BS, Gute P, Knupp B, Staszewski S, Helm EB. Changing incidence of AID-defining illnesses in the era of antiretroviral combination therapy. AIDS 1997, 11:1731-1738.
3. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Further J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998, 338:853-860.
4. Flexner C. HIV-protease inhibitors. N Engl J Med 1998, 338:1281-1292.
5. Schmidt ME. Neuroimaging and the pharmacological treatment of schizophrenia. In: Breier A, Tran PV, Herrea JM, Tollefson GD, Bymaster FP, editors. Current issues in the psychopharmacology of schizophrenia. Philadelphia: Lippincott Williams and Wilkins; 2001.
6. Kane JM, Honigfeld C, Singer J, Meltzer H, and the Clozaril Collaborative Study Group. Clozapine for the treatment resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988, 45:789-796.
7. Arvanitis LA, Miller BG, and the Seroquel Trial 13 Study Group. Multiple fixed doses of 'seroquel' (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiatry 1997, 42:233-246.
8. Beasley CM, Hamilton SH, Crawford AM, Dellva MA, Tollefson GD, Tran PV, et al. Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial. Eur J Neuropsychopharmacol 1997, 7:125-137.
9. Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan GW, et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993, 13:25-40.
10. Tandon R, Harrigan E, Zorn SH. Ziprasidone: a novel antipsychotic with unique pharmacology and therapeutic potential. J Serotonin Res 1997, 4:159-177.
11. Jeste DV, Rockwell E, Harris MJ, Lohr JB, Lacro J. Conventional vs. newer antipsychotics in elderly patients. Am J Geriatr Psychiatry 1999, 7:70-76.
12. Jeste DV, Alexopoulos GS, Bartels SJ, Cummings J, Gallo JJ, Gottlieb GL, et al. Consensus statement: the upcoming crisis in geriatric mental health: challenges and opportunities. Arch Gen Psychiatry 1999, 56:848-853.
13. Lieberman R. HIV in older Americans: an epidemiologic perspective. J Midwifery Women's Health 2000, 45:176-182.
14. Centers for Disease Control and Prevention, National Center for HIV, STD, and TB Prevention, Division of HIV/AIDS Prevention-Surveillance and Epidemiology. AIDS surveillance, special data run; 2001. http://www.cdc.gov/hiv/ dhap.htm [Accessed September 2002]
15. Skiest DJ, Rubinstien E, Carley N, Gioiella L, Lyons R. The importance of comorbidity in HIV-infected patients over 55: a retrospective case-control study. Am J Med 1996, 101:605-611.
16. Saltzman RL, Peterson PK. Immunodeficiency of the elderly. Rev Infect Dis 1987, 9:1127-1139.
17. Hinkin CH, Castellon SA, Atkinson JH, Goodkin K. Neuropsychiatric aspects of HIV infection among older adults. J Clin Epidemiol 2001, 54 (Suppl):S44-S52.
18. Kalichman SC, Kelly JA, Johnson JR, Bulto M. Factors associated with risk for HIV infection among chronic mentally ill adults. Am J Psychiatry 1994, 151:221-227.
19. Tynes LL, Sautter FJ, McDermont BE, Winstead DK. Risk of HIV infection in the homeless and chronically mentally ill. South Med J 1993, 86:276-281.
20. Cournos F, Guido JR, Coomaraswamy S, Meyer-Bahlburg H, Sugden R, Horwath E. Sexual activity and risk of HIV infection among patients with schizophrenia. Am J Psychiatry 1994, 151:228-232.
21. Sewell DD. Schizophrenia and HIV. Schizophr Bull 1996, 22:465-473.
22. Walkup J, Sambamoorthi U, Crystal S. Incidence and consistency of antiretroviral use among HIV-infected medicaid beneficiaries with schizophrenia. J Clin Psychiatry 2001, 62:174-178.
23. Wellons MF, Sanders L, Edwards LJ, Bartlett JA, Heald AE, Schmader KE. HIV infection: Treatment outcomes in older and younger adults. J Am Geriatr Soc 2002, 50:603-607.
24. Kilbourne AM, Justice AC, Rabeneck L, Rodriguez-Barradas M, Weissman S, for the VACS 3 Project Team. General medical and psychiatric comorbidity among HIV-infected veterans in the post-HAART era. J Clin Epidemiol 2001, 54 (Suppl):S22-S28.
25. Knobel H, Guelar A, Valldecillo G, Carmona A, Gonzalez A, Lopez-Colomes JL, et al. Response to highly active antiretroviral therapy in HIV-infected patients age 60 years or older after 24 months follow-up. AIDS 2001, 15:1591-1593.
26. McKinnon K, Carey MP, Cournos F. Research on HIV, AIDS, and severe mental illness: recommendations from the NIMH National Conference. Clin Psychol Rev 1997, 17:327-331.
27. Harris MJ, Jeste DV, Gleghorn A, Sewell DD. New-onset psychosis in HIV-infected patients. J Clin Psychiatry 1991, 52:369-376.
28. Sewell DD, Jeste DV, Atkinson JH, Heaton RK, Hesselink JR, Wiley C, et al. HIV-associated psychosis: a study of 20 cases. Am J Psychiatry 1994, 151:237-242.
29. Alciati A, Fusi A, Monforte A, Coen M, Ferri A, Mellado C. New-onset delusions and hallucinations in patients infected with HIV. J Psychiatry Neurosci 2001, 26:229-234.
30. De Ronchi D, Faranca I, Forti P, Ravaglia G, Borderi M, Manfredi R, et al. Development of acute psychotic disorders and HIV-1 infection. Int J Psychiatry Med 2000, 30:173-183.
31. Halstead S, Riccio M, Harlow P, Oretti R, Thompson C. Psychosis associated with HIV infection. Br J Psychiatry 1988, 153: 618-623.
32. El-Mallakh RS. HIV-related psychosis. J Clin Psychiatry 1992, 53:293-294.
33. El-Mallakh RS. Mania in AIDS: dinical significance and theoretical considerations. Int J Psychiatry Med 1991, 21:383-391.
34. Koutsilieri E, Sopper S, Scheller C, ter Meulen V, Riederer P. Involvement of dopamine in the progression of AIDS dementia complex. J Neural Transm 2002, 109:399-410.
35. Dore GJ, Correll PK, Li Y, Kaldor JM, Cooper DA, Brew BJ. Changes to AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS 1999, 13:1249-1253.
36. Ellis RJ, Gamst AC, Capparellli E, Spector SA, Hsia K, Wolfson T, et al. Cerebrospinal fluid HIV RNA originates from both local CNS and systemic sources. Neurology 2000, 54:927-936.
37. Sewell DD, Jeste DV, McAdams LA, Bailey A, Harris MJ, Atkinson JH, et al. Neuroleptic treatment of HIV-associated psychosis. Neuropsychopharmacology 1994, 10:223-229.
38. McDaniel JS, Purcell DW, Farber EW. Severe mental illness and HIV-related medical and neuropsychiatric sequelae. Clin Psychol Rev 1997, 17:311-325.
39. Shedlack KJ, Soldato-Couture C, Swanson CL. Rapidly progessive tardive dyskensia in AIDS. Biol Psychiatry 1994, 35:147-148.
40. Ayuso JL. Use of psychotropic drugs in patients with HIV infections. Drugs 1994, 47:599-610.
41. Hriso E, Kuhn T, Masdeu JC, Grundman M. Extrapyramidal symptoms due to dopamine-blocking agents in patients with AIDS encephalopathy. Am J Psychiatry 1991, 148:1558-1561.
42. Caligiuri MP, Jeste DV, Lacro JP. Antipsychotic-induce movement disorders in the elderly: epidemiology and treatment recommendations. Drugs Aging 2000, 17:363-384.
43. Berger JR, Kumar M, Kumar A, Fernandez JB, Levin B. Cerebrospinal fluid dopamine in HIV infection. AIDS 1994, 8:67-71.
44. Berger JR, Nath A. HIV dementia and the basal ganglia. Intervirology 1997, 40:122-131.
45. Factor SA, Podskalny GD, Barron KD. Persistent neuroleptic-induced rigidity and dystonia in AIDS dementia complex: a clinico-pathological case report. J Neurol Sci 1994, 127: 114-120.
46. Wiley CA, Baldwin M, Achim CL. Expression of HIV regulatory and structural mRNA in the central nervous system. AIDS 1996, 10:843-847.
47. Gisslen M, Larsson M, Norkrans G, Fuchs D, Wachter H, Hagberg L. Tryptophan concentrations increase in cerebrospinal fluid and blood after zidovudine treatment in patients with HIV type 1 infection. AIDS Res Hum Retroviruses 1994, 10:947-951.
48. Mirsattari SM, Power C, Nath A. Parkinsonism with HIV infection. Mov Disord 1998, 13:684-689.
49. Jeste DV, Lacro JP, Bailey A, Rockwell E, Harris J, Caligiuri MP. Lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients. J Am Geriatr Soc 1999, 47:716-719.
50. Beasley CM, Tollefson GD, Tran PV. Efficacy of olanzapine: an overview of pivotal clinical trials. J Clin Psychiatry 1997, 58: 7-12.
51. Simpson GM, Lindenmayer JP. Extrapyramidal symptoms in patients treated with risperidone. J Clin Psychopharmacol 1997, 17:194-201.
52. Kane JM, Woerner MG, Pollack S, Safferman AZ, Lieberman JA. Does clozapine cause tardive dyskinesia? J Clin Psychiatry 1993, 54:327-330.
53. Singh AN, Catalan J. Risperidone in HIV-related manic psychosis. Lancet 1994, 344:1029-1030.
54. Singh AN, Golledge H, Catalan J. Treatment of HIV-related psychotic disorders with risperidone: a series of 21 cases. J Psychosom Res 1997, 42:489-493.
55. Dettling M, Muller-Oerlinghausen B, Britsch P. Clozapine treatment of HIV-associated psychosis - too much bone marrow toxicity? Pharmacopsychiatry1998, 31:156-157.
56. Maha A, Goetz K. Risperidone for the treatment of delusional disorder due to HIV disease. J Neuropsychiatry Clin Neurosci 1998, 10:111.
57. Meyer JM, Marsh J, Simpson G. Differential sensitivities to risperidone and olanzapine in a human immunodeficiency virus patient. Biol Psychiatry 1998, 44:791-794.
58. Zilikis N, Nimatoudis I, Kiosses V, Ierodiakonou C. Treatment with risperidone of an acute psychotic episode in a patient with AIDS. Gen Hosp Psychiatry 1998, 20:384-385.
59. Lera G, Zirulnik J. Pilot study with clozapine in patients with HIV-associated psychosis and drug-induced parkinsonism. Mov Disord 1999, 14:128-131.